MedTrace Logo

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

NCT05813925 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2026-01-22

No results posted yet for this study

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

Conditions

  • Obesity or Overweight

Interventions

DRUG

Cagrilintide

Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

DRUG

Semaglutide

Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

DRUG

Placebo Semaglutide

Participants will receive placebo matched to semaglutide

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency' (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2025-01-17
Completion
2025-03-07
FDA Drug
Yes

Countries

  • Japan
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813925 on ClinicalTrials.gov